Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate
Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the development of IBI3009, a novel DLL3-targeted antibody-drug ... Read More